Dietary supplementation with Goji berries enhances Bifidobacteria and butyrate-producing bacteria growth, resulting in potential preventative effects against colitis.
Experimental Study Colitis Goji Berry Gut Microbiota
In this study, two groups of IL-10-deficient mice were used, with one group kept on a standard rodent diet and the other supplemented with a Goji berry diet, accounting for 1% of the dry feed's weight. These diets were maintained for 10 weeks. Colonic tissues and fecal contents were collected and analysed after this period.
In the Goji supplemented group, there was a noticeable decrease in colonic pathobiological scores, a reduced mRNA expression of Il17a and Tgfb1, and an increase in Muc1 expression and fecal IgA content. Goji supplementation was found to increase the Actinobacteria phylum, leading to a surge in Bifidobacteria in the gut microbiota. Dietary Goji also promoted the growth of butyrate-producing bacteria like the Lachnospiraceae-Ruminococcaceae family and Roseburia species under Clostridium cluster XIVa, with Clostridium leptum and Fecalibacterium prazusnitzii significantly increased in the Goji group. Interestingly, the gene encoding butyryl-coenzyme A CoA transferase, crucial for butyrate synthesis in these bacteria, showed a sixfold increase in the fecal samples from the Goji group, correlating with higher fecal butyrate levels. This phenomenon indicates that Goji berry's dietary inclusion results in Bifidobacteria proliferation and the butyrate-producing bacteria's blooming, which may have cross-feeding relationships providing preventative effects against colitis.
View Article